全球心脏标志物检测市场 – 行业趋势和 2031 年预测

心脏标志物检测市场分析和规模

心脏标志物检测中的风险分层是指使用肌钙蛋白、CK-MB 和 B 型利钠肽 (BNP) 等生物标志物来评估患者未来发生心血管事件的可能性。这些标志物的水平升高表明心肌受损、心脏压力或功能障碍，可帮助医疗保健提供者将患者分为不同的风险组。这种分层可指导治疗决策、确定监测强度并预测预后，从而根据患者的心血管风险状况制定个性化管理计划。因此，心脏标志物检测在优化患者结果方面发挥着关键作用，因为它可以识别出那些可能从更积极的干预措施或更密切的监测中受益的高风险人群。

2023 年全球心脏标志物检测市场规模为 126.8 亿美元，预计到 2031 年将达到 254.6 亿美元，2024 年至 2031 年预测期内的复合年增长率为 9.10%。

除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察之外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分       

Market Definition

Cardiac marker testing involves measuring specific substances released into the bloodstream when the heart is damaged or under stress. These markers include enzymes such as creatine kinase (CK-MB) and troponins (troponin T and troponin I), as well as proteins such as myoglobin. Elevated levels of these markers help diagnose conditions such as myocardial infarction (heart attack) or other cardiac injuries. Cardiac marker testing is crucial for early detection, monitoring treatment effectiveness, and assessing the extent of cardiac damage in clinical settings.

Cardiac Marker Testing Market Dynamics

Drivers                                                                                          

• Rise in Geriatric Population

The rising age of the global population leads to a higher prevalence of age-related cardiovascular diseases, such as heart failure, myocardial infarction, and other cardiac conditions. Older adults are more prone to these conditions, necessitating regular monitoring and early detection through cardiac marker tests. This demographic shift increases the demand for diagnostic tools to manage and treat cardiovascular diseases effectively, thereby driving the growth of the cardiac marker testing market. Enhanced healthcare infrastructure and the emphasis on improving the quality of life for the elderly further boost the need for advanced cardiac diagnostic solutions.

• Rising Advancements in Diagnostic Technologies

Innovations such as high-sensitivity assays, automated analyzers, and point-of-care testing devices have greatly enhanced the accuracy, speed, and convenience of cardiac marker tests. These technological improvements allow for earlier and more precise detection of cardiac events, facilitating timely medical intervention and improving patient outcomes. Additionally, the integration of digital health solutions, such as smartphone-based diagnostics, is expanding access to cardiac marker testing, further propelling market growth. As technology continues to evolve, it is expected to drive continued advancements and adoption in cardiac marker testing worldwide.

Opportunities

• Increasing Strategic Collaborations

Collaborations between healthcare providers, diagnostic companies, and research institutions foster innovation and development of advanced cardiac marker tests. These collaborations enable the sharing of expertise, resources, and technology, leading to the creation of more sensitive and specific diagnostic tools. Joint ventures and alliances also facilitate faster regulatory approvals and market entry, expanding the availability of cutting-edge diagnostic solutions. Additionally, strategic collaborations often result in enhanced distribution networks and better access to emerging markets, ultimately driving the growth and adoption of cardiac marker testing worldwide.

• Expansion of Point-of-Care Testing (POCT)

POCT enables rapid, on-site diagnostic testing for cardiac markers, providing immediate results in various healthcare settings, including emergency departments, clinics, and even at patients' bedsides. This reduces the time to diagnosis and treatment for acute cardiac events, improving patient outcomes. The convenience and accessibility of POCT devices facilitate early detection and continuous monitoring of cardiovascular conditions. Advancements in POCT technology, combined with increasing adoption by healthcare providers, are propelling the growth of the cardiac marker testing market, ensuring timely and efficient cardiac care.

Restraints/Challenges

• High Initial Costs

Advanced diagnostic technologies and the reagents used for cardiac marker tests are often expensive, making these tests less affordable for many healthcare facilities, particularly in low- and middle-income countries. The initial investment in equipment and ongoing operational costs can be prohibitive, limiting widespread adoption. This cost barrier can prevent healthcare providers from implementing routine cardiac marker testing, reducing access to timely and accurate diagnostics for patients with cardiovascular conditions.  

• Lack of Skilled Professionals

Interpreting cardiac marker test results accurately requires specialized training and expertise, which many healthcare facilities, particularly in low-resource settings, may lack. This shortage of trained personnel can lead to misdiagnosis or delayed diagnosis, undermining the effectiveness of cardiac marker testing. Moreover, the complexity of some testing technologies necessitates proper handling and analysis to ensure reliable results.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In May 2022, Quidel Corporation launched the "Triage Cardiac Panel," FDA-approved for use in emergency departments to aid in diagnosing myocardial infarction. This panel specifically measures levels of creatine kinase MB, myoglobin, and troponin I, critical markers indicative of heart damage. The introduction of this diagnostic tool enhances rapid decision-making in emergency settings, facilitating quicker intervention and treatment for patients suspected of acute cardiac events
• In January 2022, PocDoc launched a revolutionary smartphone-based cardiovascular test aimed at pharmacies, private healthcare providers, and NHS facilities. This innovation covers a comprehensive five-market lipid panel, promising significant cost savings for the NHS through reduced staffing needs. This advancement aligns with the trend towards personalized diagnostics and decentralized healthcare solutions, potentially transforming how cardiovascular health is managed and monitored

Cardiac Marker Testing Market Scope

The market is segmented on the basis of type, product, disease and type of testing. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Type

• Troponin I and T
• Creatine kinase-MB (CK-MB)
• Brain Natriuretic peptide (Bnp or Nt-Probnp)
• Myoglobin
• HIGH-sensitivity C-reactive protein (hs-CRP)
• Other Biomarkers

Product

• Instruments
  • Chemiluminescence
  • Immunofluorescence
  • ELISA
  • Immunochromatography
• Reagents
• Kits

Disease

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Atherosclerosis
• Ischemia

Type of Testing

• Laboratory Testing
  • Hospital Labs
  • Refrence Labs
  • Contract Labs
• Academic Institutions
• Point-Of-Care Testing

心脏标志物检测市场区域分析/见解

对市场进行分析，并按上述国家、类型、产品、测试类型和疾病提供市场规模洞察和趋势。      

市场报告涉及的国家包括美国、加拿大、墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区其他地区 (APAC)、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲其他地区 (MEA)、巴西、阿根廷和南美洲其他地区。   

北美占据市场主导地位，因为该地区在研发方面投入了大量资金，促进了诊断技术的创新和技术进步。雅培、丹纳赫等主要全球企业总部都设在北美，确保了其强大的影响力和广泛的产品供应。该地区受益于完善的医疗保健基础设施，支持广泛采用先进的诊断解决方案。

由于心血管疾病发病率不断上升，亚太地区市场有望快速增长，利润丰厚。旨在提高患者和医生对早期诊断重要性的认识的公私合作计划正在推动这一增长。医疗支出的增加和诊断技术的进步进一步促进了该地区诊断解决方案市场的扩大，使其成为寻求医疗保健和诊断增长机会的公司关注的重点领域。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及由于来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

该市场还为您提供每个国家/地区资本设备医疗支出增长、市场上不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对市场的影响的详细市场分析。数据适用于 2016-2021 年的历史时期。

竞争格局和心脏标志物检测市场分析

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对表观遗传学诊断市场的关注有关。

市场上的一些主要参与者包括：

• F. Hoffmann-La Roche Ltd（瑞士）
• 雅培（美国）
• 西门子（德国）
• 丹纳赫（美国）
• 生物梅里埃公司（法国）
• Ortho Clinical Diagnostics（美国）
• Randox Laboratories Ltd（英国）
• BG 医药（美国）
• HUMAN 公司（德国）
• Bhat Bio-tech India Private Limited（印度）
• 默克集团（德国）
• PerkinElmer Inc.（美国）
• QIAGEN（荷兰）
• 安捷伦科技公司（美国）
• 布鲁克 (美国)
• Epigenomics AG（德国）
• MESO SCALE DIAGNOSTICS, LLC（美国）
• EKF Diagnostics Holdings plc.（英国）
• Nexus-Dx（美国）
• LifeSign LLC.（美国）
• DIALAB GmbH（奥地利）
• 贝克曼库尔特公司（美国）

SKU-26277